title: Atazanavir-related hyperbilirubinaemia is not highlighted in the British National Formulary.
authors.forename: C
authors.initials: C
authors.lastname: Bradbeer
authors.forename: S
authors.initials: S
authors.lastname: Ngwenya
authors.forename: P
authors.initials: P
authors.lastname: Baker
authors.forename: M
authors.initials: M
authors.lastname: George
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000069446:Atazanavir Sulfate; D003695:Delivery of Health Care / Q000592:standards*; D005260:Female; D005858:Germany; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced* / Q000175:diagnosis; D007565:Jaundice / Q000139:chemically induced / Q000175:diagnosis; D009842:Oligopeptides / Q000009:adverse effects* / Q000627:therapeutic use; D010602:Pharmacopoeias as Topic / Q000592:standards*; D017410:Practice Guidelines as Topic; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D012017:Referral and Consultation; D006113:United Kingdom
chemical_list: D019380:Anti-HIV Agents; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate